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platelet number was 198000 in high, and 213000 in low-
intermediate group. Out of 35 patients who were checked
for both HCVRNA and Anti-HCV 68.5% (n = 24) positive for
both Anti-HCV and HCVRNA, while 31.5% were positive for
anti-HCV but HCVRNA negative. These patients are believed
to be immune to HCV.
Conclusion: With the introduction of HCV quantiﬁcation
method as a diagnostic tool, it became possible to
distinguish truly HCV immune patients who were considered
as HCV infected before. We noticed positive correlation HCV
viral load with liver enzymes. The method allows treatment
monitoring for the ﬁrst time in Mongolia.
PP-144 Inﬂuence of predictor variables on side effects
of the treatment with PEG Interferon Alfa 2a
plus ribavirin in chronic hepatitis C
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Aim: Prediction of main side effects of chronic hepatitis C
treatment with Peg-IFN a2a and ribavirin.
Methods: We evaluated in 55 patients treated with
Peg-IFN a-2a plus ribavirin numerous predictors inﬂuence
on main side effects (dichotomous dependent variable) on
different date of therapy: ﬂu-like syndrome, leucopenia,
thrombocytopenia, weigh lose, fatigue, depression,
insomnia, artralgia, myalgia, anorexia, nausea, anemia,
headache, alopecia, pruritus and rash. Statistic analyses
was done by SPSS 11.0 with binary logistic regression. Eleven
independent variables, such as age, gender, body mass in-
dex (BMI), disease limitation, pretreatment with standard or
Peg-IFN, presence of antibodies to HBV, alcohol abuse, drug
abuse, genotype (1b, 1a, 2 and 3), level of ferritin (FERR),
viral load (VL), were coding as dichotomous or categorical.
Results: Already on ﬁrst month of the treatment probability
of myalgia calculated by formula 1:
log
p
1 p
= 1.33 1.34HBV(1)
3.32 disease limitation(1)
2.64 disease limitation(2),
(1)
where HBV(1) HBcAb; disease limitation(1) long-standing
of HCV-infection up to 5 years; disease limitation(2) 5 10
years. Probability of ﬂu-like syndrome on ﬁrst month of
therapy is calculated by formula 2:
log
p
1 p
= 2.54
+ 2.69 genotype 1a
+ 8.07 genotype 2
+ 2.38 genotype 3
+ 2.67 high VL
1.94 alcohol abuse.
(2)
Risk factors were genotype 1a (OR = 14.7) and highVL
(OR = 1.45).
Signiﬁcant model was received for IVDU (p = 0.005), alcohol
abuse, HBV infection, high FERR and VL inﬂuence on weight
loss during last months of therapy (formula 3):
log
p
1 p
= 1.73 4.36 IVDU 1.78 high FERR
0.038 high VL 0.096 alcohol abuse
+ 1.55HBcAb.
(3)
Conclusions: Development of side effects of the treatment
with pegylated IFN-alfa-2a and ribavirin depends on some
predictor factors.
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Introduction: There is a growing evidence of intergenotypic
recombination in HCV. In this paper we report a patient
infected by HCV 1b and, probably, recombinant 2/1b that is
detected in peripheral blood mononuclear cells (PBMC).
Case description: Patient S., male, 31 years old admitted
in January 2009. HCV viral load in serum before treatment
9,630,000 IU/ml. HCV genotyping by sequencing 5′UTR and
NS5A. According to phylogenetic analysis NS5A belongs to 1b
(sera and PMBC), 5′UTR from serum to 1b, from PBMC to
genotype 2. Due to discordant results recombinant 2/1b
in PBMC can be suspected. NS5A interferon sensitivity
determining region (ISDR) contains mutation R2218H.
Laboratory: ALT 71U/l, AST 62U/l, GGT 36U/l. Liver
biopsy: HAI 8, ﬁbrosis 1. Immunohistochemically HCV NS3
was detected in lobules and tracts. Elevated CD16 and
CD20 was found in lymphoid follicules of portal tracts.
Patient received treatment with pegintron (1.5mg/kg BW)
plus ribavirin (1000mg/day) for 48 weeks. Virological and
biochemical response were achieved on 12 wk and remained
until the end of treatment and during follow-up. Liver biopsy
after treatment: HAI 3, ﬁbrosis 0. Immunohistochemically
NS3 was still detected in lobules and tracts, CD16 and CD20
decreased in portal tracts.
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PP-146 Establishment of highly efﬁcient full-length
HCV 1b genome cell culture system by inserting
long distant structural fragment into replicon
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J.J. Wang1, S.W. Liu2, Y.S. Wu2. 1Nanfang Hospital,
Southern Medical University, 2Southern Medical University,
China
Objectives: To establish a full-length genome of hepatitis C
virus (HCV) 1b, the dominant strain in China, cell culture
system for further study.
Methods: The 5′-end of half HCV-1b genome (5.2kb) was
ampliﬁed from Chinese chronic hepatitis C patients’ seral
samples with the reﬁned long distant RT-PCR technique. The
full length recombinant plasmid of HCV 1b was constructed
by inserting the long distant structural regions directly into
HCV 1b replicon containing the non-structural regions. In
vitro transcribed genomic HCVRNA was transfected into
Huh7.5.1 cells by liposome-mediated method. The real
time quantitative RT-PCR, Western Blot, inoculation of
naı¨ve Huh7.5.1 cells, immune ﬂuorescence and titration
of infectious HCV were used for identiﬁcation of HCV
replication and presence of infectious virion.
Results: The real time quantitative RT-PCR assay revealed
the highest titer of HCV was 6.5×107 copies/mL in the
cultural supernatants. While both Western Blot analysis and
immune ﬂuorescence conﬁrmed the expression of HCV core
protein in the transfected cells. Subsequent infection of
naı¨ve Huh7.5.1 cells with supernatant of HCV cell culture
resulted in high levels of HCV proteins and RNAs.
Conclusions: These results demonstrate the successful
establishment of a HCV 1b culture system by the new
strategy of inserting long distant structural amplicon into
replicon that produces infectious virus, which will allow the
study of each aspect of the entire HCV life cycle and related
studies.
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Background: HCV infection became a worldwide threat
to human health, which can led to chronic hepatitis C,
cirrhosis and hepatoma. As only human and chimpanzees are
susceptible to hepatitis C virus, the progress of HCV research
has been obstructed due to the absence of a reliable small
primate animal model. GB virus B (GBV-B), being very close
to hepatitis C virus (HCV) phylogenetically, can replicate
effectively in vivio of common marmosets, that has been
made an attractive surrogate virus for HCV replication study.
It was reported that HCV NS2-NS3 protease, NS3 protease
and NS4A complex are critical for virus maturation and
replication. The construction of chimeric GB Virus B with
Hepatitis C NS2-NS4A region can be used to develop a
marmoset model for antiviral and immune studies.
Methods: RT-PCR and overlapping PCR were applied to
complete jointing gene fragments and T7 transcription kit
was used to produce chimeric GBV-B/HCV infectious RNA
in vitro.
Results: A chimeric clone originating from GB virus B
(GBV-B), in which GBV-B NS2-NS4A region are replaced by
analogous sequence of the HCV genome, was constructed.
Conclusions: This chimeric clone lays the roots for a
surrogate model of Hepatitis C virus, insights into HCV
replication mechanism and further HCV NS3 epitope-based
research.
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Background: Hepatitis C virus (HCV) infection is a major
public health problem in China. However systematic studies
conducted on mechanism of recovery and chronic infection
with HCV are little known. A detailed study was carried
out to investigate IFN-a and IFN-g correlating to antibody
reactivity and viral factors in the population of recovered
and chronic HCV infection from blood donors.
Methods: 160 plasmas samples reactive with anti-HCV
assays were collected from blood donors in Guangdong and
Beijing. HCV antibody reactivity was presented as S/CO by
at least three EIA assays. All samples were tested for ALT
and viral load, conﬁrmed by nested-PCR, and classiﬁed as
three statuses of recovery (RNA /Ab+), chronic (RNA+/Ab+)
and false positive (RNA /Ab ) infections. Productions of
IFN-a and IFN-g in the serum were also quantiﬁed
by ELISA. The genotypes of HCV from chronic samples
were phylogenetically analyzed with 5′-NCR sequences
(215 218bp).
Results: 45 recovery, 76 chronic and 39 false positive of 160
HCV antibody positive plasmas were ﬁnally conﬁrmed. The
rate of recovered HCV infected individuals in blood donors
was 37.2% proximately. 63 HCV strains were genotyped,
